Microrna 192 gene expression in type II diabetic nephropathy
Egyptian Journal of Hospital Medicine [The]. 2017; 68 (1): 885-893
em En
| IMEMR
| ID: emr-189923
Biblioteca responsável:
EMRO
Background: diabetic nephropathy [DN] is the common cause of kidney failure in patients with diabetes mellitus. MicroRNAs [miRNAs] are short non-coding RNAs of about 22 nucleotides which recently have been shown to play vital roles in mammalian gene expression
Aim of the study: was to investigate the role of miRNA-192 in the pathogenesis of diabetic nephropathy and disease progression. Patients and Method: Sixty five patients with uncontrolled diabetes mellitus, they were subdivided into; thirty nine patients with normoalbuminuria [<20mg/L]; their ages ranged between 48-67 years and the onset of disease between 1-5 years; twenty six patients with microalbuminuria [20-200 mg/L], their ages ranged between 47-66 years and the onset of disease between 5-15 years, in addition to twelve apparently healthy individuals as control; their ages ranged between 51-67 years. Serum Transforming growth factor beta [TGF-beta], Interleukin 18 [IL-18] were determined using ELISA technique, the expression level of miRNA-192 in whole blood using [RT-PCR] was determined, other biochemical parameters as fasting plasma glucose [FPG], glycated haemoglobin [HbA1c], lipid profile and creatinine were estimated using commercial available kits. Patients were given written contest
Results: the level of miRNA-192 expressions was significantly lower in microalbuminuria group when compared to normoalbuminuria group. Serum level of IL-18 and TGF-beta were significantly higher in both patient groups when compared to control group and their levels were significantly higher in microalbuminuria group than normoalbuminuria group
Conclusion: together with TGF-beta1 and IL-18, miRNA- 192 may not only be used as molecular biomarker in diabetic microvascular complications but also as early marker of alterations in specific biological processes in the kidney
Aim of the study: was to investigate the role of miRNA-192 in the pathogenesis of diabetic nephropathy and disease progression. Patients and Method: Sixty five patients with uncontrolled diabetes mellitus, they were subdivided into; thirty nine patients with normoalbuminuria [<20mg/L]; their ages ranged between 48-67 years and the onset of disease between 1-5 years; twenty six patients with microalbuminuria [20-200 mg/L], their ages ranged between 47-66 years and the onset of disease between 5-15 years, in addition to twelve apparently healthy individuals as control; their ages ranged between 51-67 years. Serum Transforming growth factor beta [TGF-beta], Interleukin 18 [IL-18] were determined using ELISA technique, the expression level of miRNA-192 in whole blood using [RT-PCR] was determined, other biochemical parameters as fasting plasma glucose [FPG], glycated haemoglobin [HbA1c], lipid profile and creatinine were estimated using commercial available kits. Patients were given written contest
Results: the level of miRNA-192 expressions was significantly lower in microalbuminuria group when compared to normoalbuminuria group. Serum level of IL-18 and TGF-beta were significantly higher in both patient groups when compared to control group and their levels were significantly higher in microalbuminuria group than normoalbuminuria group
Conclusion: together with TGF-beta1 and IL-18, miRNA- 192 may not only be used as molecular biomarker in diabetic microvascular complications but also as early marker of alterations in specific biological processes in the kidney
Buscar no Google
Índice:
IMEMR
Idioma:
En
Revista:
Egypt. J. Hosp. Med.
Ano de publicação:
2017